Hepatitis delta virus (HDV) replicates by RNA-dependent RNA
synthesis according to a double rolling circle model. Also synthesized during replication is a 0.8-kb, polyadenylated mRNA encoding the hepatitis delta antigen (HDAg). It has been proposed that this mRNA
species represents the initial product of HDV RNA replication; subsequent production of genomic-length HDV RNA relies on suppression of the HDV RNA polyadenylation signal by HDAg. However, this model was
based on studies which required the use of an HDV cDNA copy to initiate
HDV RNA replication in cell culture, thus introducing an artificial
requirement for DNA-dependent RNA synthesis. We have now used an HDV
cDNA-free RNA transfection system and a method that we developed to
detect specifically the mRNA species transcribed from the HDV RNA
template. We established that this polyadenylated mRNA is 0.8 kb in
length and its 5' end begins at nucleotide 1631. Surprisingly, kinetic
studies showed that this mRNA continued to be synthesized even late in
the viral replication cycle and that the mRNA and the genomic-length
RNA increased in parallel, even in the presence of HDAg. Thus, a switch
from production of the HDAg mRNA to the full-length HDV RNA does not
occur in this system, and suppression of the polyadenylation site by
HDAg may not significantly regulate the synthesis of the HDAg mRNA, as previously proposed. These findings reveal novel insights into the
mechanism of HDV RNA replication. A new model of HDV RNA replication and transcription is proposed.
 |
INTRODUCTION |
Hepatitis delta virus (HDV) is an
unusual subviral pathogen associated with fulminant and chronic
hepatitis. HDV depends on hepatitis B virus coinfection to form
infectious virions, since it uses hepatitis B surface antigen to form
its viral envelope (25). It contains a single-stranded
circular RNA genome of 1.7 kb (14, 22, 31), which can
replicate in the absence of hepatitis B virus (4, 7). Three
genotypes of HDV strains which differ by as much as 35% in nucleotide
sequence (1) and may also differ in pathogenicity have been
described. HDV replicates through a double rolling circle mechanism,
generating multiple-length genomic and antigenomic-sense HDV RNAs,
which are processed into monomeric circular HDV genomic and antigenomic
RNAs (4, 15, 29). This replication process is presumably
carried out by cellular RNA polymerase II (pol II), since it is
inhibited by
-amanitin (21).
Also detected in HDV-infected liver tissue and some cultured cells
replicating HDV RNA is a polyadenylated, 800-nucleotide (nt)
antigenomic-sense HDV RNA (4, 8) that contains the open
reading frame (ORF) for a protein termed hepatitis delta antigen
(HDAg). This is the only protein produced by HDV but is usually
composed of two forms: the small form (24 kDa) is required for viral
RNA replication (13), while the large form (27 kDa) is a
dominant negative inhibitor of HDV replication (3) and is
required for virion assembly (2, 27). The production of large HDAg is the result of an RNA editing event during HDV replication (18), which extends the HDAg ORF for an additional 19 amino acids. This editing event is reported to occur at a late stage in the
viral replication cycle, such that when the large form of HDAg is
synthesized, HDV RNA replication will stop and virus assembly will
begin.
The nature of the 0.8-kb mRNA has been controversial, since it is very
difficult to detect in most cells replicating HDV RNA. It was proposed
that this mRNA represents the initial product of HDV RNA replication;
upon reaching the HDV RNA polyadenylation signal, the nascent
transcript is polyadenylated and released as the HDAg-encoding mRNA
(8, 10). The HDAg synthesized from this mRNA, in turn,
inhibits the polyadenylation signal, thus allowing subsequent rounds of
RNA replication to proceed beyond the polyadenylation signal, producing
genomic-size (1.7-kb) HDV RNA (10). This model thus explains
the paucity of the 0.8-kb mRNA species (15). Indeed,
experimental evidence has shown that HDAg (both the small and large
forms) can negatively regulate the HDV polyadenylation signal within an
HDV cDNA construct (9, 10).
There is, however, a major conceptual flaw in this model. The mRNA for
the large HDAg will not be synthesized under this scenario since RNA
editing does not occur until later in infection, when a large amount of
small HDAg has already been produced. This question has been difficult
to address because the amount of the 0.8-kb RNA is very low or even
undetectable in HDV-infected human or chimpanzee liver tissues or in
cell cultures and transgenic mice (24) which actively
replicate HDV RNA. A further complication is that HDV RNA replication
has always been studied by using an HDV cDNA transfection approach (for
a review, see reference 15). We have previously
shown that the HDV cDNA contains several bidirectional promoters
(19). Thus, the study of RNA transcription or replication from HDV RNA in these systems is compromised by the potential initiation of transcription from the cryptic promoters within the HDV
cDNA. So far, the only successful HDV RNA transfection system reported
is the transfection of HDV RNA into cells stably expressing an
HDAg-encoding mRNA (7). Again, this artificial cDNA-based
mRNA has complicated the study of authentic HDAg-encoding mRNA
synthesis.
In this study, we developed an RNA transfection approach which was
totally devoid of HDV cDNA and could detect specifically HDAg-encoding
mRNA transcribed from HDV RNA. Using this approach, we found that HDV
mRNA was abundantly synthesized throughout the HDV life cycle. Thus,
contrary to the current model of HDV RNA transcription and replication
(8, 10, 15, 16), there was no detectable inhibition of HDV
mRNA synthesis by HDAg. Furthermore, the initiation point of the 0.8-kb
mRNA may differ from the initiation point of HDV genomic RNA, again
contradicting the current model. These findings provide novel insights
into the mechanism of HDV RNA replication. A new model of HDV RNA
replication and transcription is proposed.
 |
MATERIALS AND METHODS |
Cell culture and transfection.
Ts
3 cells, which were
derived from a temperature-sensitive hamster cell line (30)
and stably express the small HDAg from an integrated cDNA copy of the
HDAg-encoding mRNA under the cytomegalovirus promoter (11),
were cultured at 33°C in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum, 100 IU of penicillin per ml,
and 100 mg of streptomycin per ml. H1
9 cells, which contain an
integrated cDNA for trimer HDV RNA (20), were cultured at
37°C in the same medium. Huh7 cells (23) were cultured at
37°C in DMEM supplemented with 10% fetal bovine serum, 100 IU of
penicillin per ml, 100 mg of streptomycin per ml, 2 mM
L-glutamate, and 1% nonessential amino acids (complete DMEM). All transfections were performed by using the DOTAP (Boehringer Mannheim) method according to the protocol provided by the
manufacturer. Briefly, 1 day prior to transfection, Ts
3 or Huh7
cells were seeded onto 60-mm-diameter dishes. On the following day, the
cells were refreshed with 5 ml of the appropriate culture medium before transfection. Cells were transfected with 5 µg of plasmid cDNA (for
Huh7 cells) or RNA (for Ts
3 cells) in 0.15 ml of transfection mixture or 10 µg of RNA (for Huh7 cells) in 0.3 ml of transfection mixture. Following incubation overnight at 33°C (Ts
3) or 37°C (Huh7), the culture medium was replaced with fresh medium and the cells
were further incubated for an additional 1 to 5 days. For experiments
involving the use of cycloheximide, 10 µg of cycloheximide per ml was
added to the culture medium 1 or 2 days posttransfection and cells were
incubated for a further 2 days.
Vectors and plasmid construction.
Plasmid PX9-I/II, which
expresses an mRNA encoding the genotype I/II chimeric HDAg under the T7
promoter, was developed from plasmid PX9, which expresses an mRNA
encoding the HDAg of the American isolate of genotype I. PX9 contains
the pT7-3 plasmid backbone and HDV nt 21 through 658 (reading through
nt 0) inserted in the BamHI-PstI site. To
construct plasmid PX9-I/II, the EcoRI (in the multiple
cloning site)-StuI (at HDV nt 1334) fragment from the
plasmid PX9 was replaced with the corresponding fragment from plasmid
63 of an HDV genotype II cDNA clone (17). Thus, genotype I
nt 21 to 1334 (reading through nt 0) were replaced with the
corresponding genotype II nt 1663 to 1334. pKS/HDVD2, which contains a
dimer HDV cDNA in a plasmid derived from plasmid pRC/CMV
(12), was used for HDV cDNA transfections.
In vitro transcription.
Genomic HDV RNA (1.9 kb), which
contains the entire HDV genome plus approximately 200 additional nt of
HDV sequence, was transcribed from pKS/HDV1.9 (12) with T7
MEGAscript (Ambion) after linearization by EcoRV digestion.
Antigenomic HDV RNA (1.9 kb) was transcribed from pKS/HDV1.9 with SP6
MEGAscript (Ambion) after linearization by SnaBI digestion.
Capped, polyadenylated mRNA for small HDAg was transcribed from PX9 or
PX9-I/II (see above) with T7 mMESSAGE mMACHINE (Ambion) after
linearization by HindIII digestion.
Northern blot analysis.
Total RNA was extracted from
transfected Ts
3 and Huh7 cells or from H1
9 cells by the
guanidinium thiocyanate method (5). Polyadenylated RNA was
isolated with an oligo(dT)-cellulose column (Sigma) according to the
standard method (28). The RNA was digested with RQ1 DNase
(Promega), treated with formaldehyde, electrophoresed through
formaldehyde-containing 1.2% agarose gels, blotted onto a
nitrocellulose membrane (Hybond C extra; Amersham), and probed with
32P-UTP-labeled HDV strand-specific riboprobes. Riboprobes
for detecting HDV RNA were transcribed with T7 RNA polymerase (Promega)
from plasmid S18 (to detect genomic HDV RNA) or S29 (to detect
antigenomic HDV RNA), following linearization with EcoRV
digestion (22). For the analysis of the H1
9 HDV mRNA,
various genomic-sense oligonucleotides (Table
1) were end labeled with
32P-ATP and T4 polynucleotide kinase (New England Biolabs).
To detect newly synthesized HDAg mRNA in Huh7 cells transfected with
genotype I HDV RNA (1.9 kb) and the chimeric genotype I/II mRNA, blots were probed with 32P-end-labeled oligonucleotide 1565, specific for the American isolate of genotype I HDV (22).
The protocol for Northern blotting using oligonucleotide probes was
adapted from that of Geliebter et al. (6). The membranes
were prehybridized for 2 h at 55°C in 7% sodium dodecyl sulfate
(SDS)-20 mM sodium phosphate (pH 7.0)-5× Denhardt's solution-5×
SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-100 µg of
salmon sperm DNA per ml and hybridized overnight at 55°C in the same
solution containing 10% dextran sulfate and 2 × 106
to 3 × 106 cpm of radiolabeled probe per ml. Blots
were washed with 3× SSC-10 mM sodium phosphate (pH 7.0)-0.5×
Denhardt's solution-5% SDS for 1 min at room temperature followed by
1 h at 55°C. Northern blots probed with full-length HDV
riboprobes were hybridized and washed as described previously
(12). RNA extracted from H1
9 cells, which express and
replicate HDV RNA from an integrated cDNA trimer, was used as a
positive control in all Northern blots. After autoradiography, computer
images were generated by using Adobe Photoshop, version 3.0, and
Canvas, version 5.0.
Western blot analysis.
Protein was extracted from
transfected Huh7 cells according to the standard method
(28). After denaturation by boiling in 2× sample buffer
(100 mM Tris-HCl [pH 6.8], 200 mM dithiothreitol, 4% SDS, 0.2%
bromophenol blue, 20% glycerol), 40 µg of protein from each sample
was loaded onto a SDS-12.5% polyacrylamide minigel. The gel was
electrophoresed for 60 to 90 min at 150 V. Proteins were then
transferred to a nitrocellulose membrane (Hybond C extra; Amersham).
Small and large HDAg were detected by the ECL (enhanced chemiluminescence) Western blot detection system (Amersham), using a
rabbit polyclonal antibody against both forms of HDAg, and visualized by autoradiography.
Primer extension analysis.
RNA extracted from Ts
3 and
Huh7 cells (as described above) and the appropriate
32P-end-labeled oligonucleotides were coprecipitated in 0.3 M sodium acetate and 2.5 volumes of ethanol. The pellet was vacuum
dried and resuspended in 8 µl of Tris-EDTA (pH 7.6) followed by the addition of 2 µl of 5× hybridization buffer (1.25 M KCl, 50 mM Tris-HCl [pH 7.4], 5 mM EDTA). The samples were incubated at 50°C for 1 h, followed by the addition of 40 µl of reverse
transcription mix (25 mM KCl, 50 mM Tris-HCl [pH 7.5], 10 mM
dithiothreitol, 3.5 mM MgCl2, 0.5 mM deoxynucleoside
triphosphates, 100 µg of bovine serum albumin per ml, 20 U of avian
myeloblastosis virus reverse transcriptase [Boehringer Mannheim]) and
further incubation for 1 h at 37°C. Reaction mixtures were
ethanol precipitated and dried as above, and the pellet was resuspended
in 4 µl of double-distilled H2O. After the addition of 2 µl of sequencing gel loading buffer (98% formamide, 10 mM EDTA [pH
8.0], 0.025% xylene cyanol FF, 0.025% bromophenol blue), the samples
were heat denatured, stored on ice, and loaded onto a 6%
polyacrylamide gel containing 8 M urea. A dideoxy sequence (Amersham)
generated from plasmid pKS/HDV1.9 primed by the same oligonucleotide
used in the primer extension was used as a nucleotide sequence marker.
 |
RESULTS |
Heterogeneity of HDAg-encoding mRNA in cDNA-based HDV replication
systems.
To characterize the mechanism of synthesis of the
HDAg-encoding mRNA, we first attempted to study this mRNA in the
various reported cDNA-based HDV replication systems in cell culture.
Three systems were studied: Huh7 cells transiently transfected with a
plasmid expressing a genomic dimer RNA of HDV, Ts
3 cells, which stably express HDAg from an integrated cDNA copy of HDAg-encoding mRNA
under the cytomegalovirus promoter (11), and H1
9 cells, which stably express an antigenomic HDV trimer RNA from an integrated cDNA copy (20). Previously it has been very difficult to
detect the 0.8-kb mRNA species in any of these systems. Based on the report that cycloheximide (CHX) treatment can inhibit mRNA translation and thereby stabilize some mRNA species (26), we treated
these cell lines with 10 µg of CHX per ml. Figure
1 shows that a polyadenylated subgenomic
HDV RNA of antigenomic sense was detected in various amounts in all
three systems. However, these putative mRNAs surprisingly ran at
different positions in denaturing agarose gels. The subgenomic mRNA in
Huh7 cells transiently transfected with an HDV cDNA was barely
detectable but appeared to have an electrophoretic mobility (Fig. 1,
lane 1) similar to that of the previously characterized mRNA identified
in cDNA-transfected COS7 cells (8). The mRNA was
polyadenylated, and its 5' end was mapped to nt 1631 (data not shown).
The amount of this mRNA was not increased by treatment with CHX (lane
2). In H1
9 cells, a significantly larger subgenomic RNA was
detected. This RNA was polyadenylated and, unlike the mRNA from
cDNA-transfected Huh7 cells, was stabilized by the addition of CHX
(Fig. 1; compare lane 5 and lane 7). The mRNA expressed in Ts
3 cells
had an electrophoretic mobility between those of the mRNA species
detected in cDNA-transfected Huh7 cells and H1
9 cells. This mRNA was
also polyadenylated and was most remarkably stabilized by CHX (Fig. 1;
compare lane 9 and lane 11). These results indicated that the HDV
subgenomic mRNA species synthesized in the three systems differed not
only in amount but also in size and structure, since they differed in
the ability to be stabilized by CHX.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 1.
Identification of subgenomic HDAg mRNAs in three cell
culture systems. RNA was isolated from H1 9, Ts 3, and Huh7 cells
transiently transfected with plasmid pKS/HDVD2, which expresses an HDV
RNA dimer of genomic sense, at day 4 posttransfection. Some cells were
treated with CHX (10 µg/ml) for 48 h before harvest. H1 9 and
Ts 3 cells were separated into poly(A)+ and
poly(A) fractions. Northern blot of HDV antigenomic sense
RNA was performed with a 32P-labeled 1.7-kb HDV
genomic-sense RNA as a probe. The following antigenomic HDV RNAs are
indicated: the 1.7-kb antigenomic HDV RNA (monomer), the H1 9 HDAg
endogenous mRNA (A), the Ts 3 endogenous HDAg mRNA (B), and the HDAg
mRNA in transiently transfected Huh7 cells (C). T, total unfractionated
RNA.
|
|
To understand the basis for the mRNA heterogeneity in these systems, we
performed primer extension studies using primer 1484 (Fig. 2A) to
determine the initiation points of these mRNAs. The subgenomic mRNA
produced in Ts
3 cells from the cDNA construct used to establish HDAg
expression in these cells (11) is predicted to begin 53 nt
before the start codon for HDAg. Primer extension analysis confirmed
this prediction (data not shown). We also performed primer extension on
RNA extracted from Ts
3 cells transfected with a 1.9-kb genomic sense
HDV RNA to determine whether a second subgenomic mRNA species expressed
from the HDV cDNA or replicating HDV RNA could be detected. No such
primer-extended product was detected (data not shown). This result
suggested that in Ts
3 cells, which synthesize an mRNA from an
integrated cDNA copy (11), HDV mRNA production from
replicating HDV RNA is severely restricted.
The subgenomic mRNA species in H1
9 cells was much larger than the
0.8-kb mRNA species and was stabilized by CHX treatment (Fig. 1, lane
7). This mRNA was detectable with a full-length genomic RNA probe (S29)
(Fig. 2B). To characterize this mRNA
species, we first used oligonucleotide probes complementary to various regions of the HDV antigenome (Fig. 2A) to determine the origin of
the additional HDV sequences seen in this mRNA. Oligonucleotide 1484, which is complementary to antigenomic HDV RNA in the HDAg ORF, bound to
both monomer-length HDV RNA and the mRNA (Fig. 2B). Oligonucleotide
902, which hybridizes to antigenomic HDV RNA in the region between the
poly(A) addition site and the ribozyme cleavage site, bound to
monomer-length antigenomic HDV RNA but not to the subgenomic mRNA,
indicating that the 3' end of this mRNA was not extended beyond the
polyadenylation signal reported for the 0.8-kb mRNA (8).
However, oligonucleotides 1634 and 63, which are complementary to
antigenomic HDV RNA sequence upstream of the previously characterized
HDAg mRNA, bound to the H1
9 mRNA, indicating that the 5'
untranslated region of this mRNA was longer than the previously
described HDAg-encoding mRNA (8). Oligonucleotides 303, 468, and 676 did not bind to the mRNA; therefore, its 5' end lay somewhere
between nt 63 and 303. Primer extension analysis of H1
9 RNA using
oligonucleotide 63 revealed a band corresponding to a 5' end located at
nt 158; this band was detectable only in the polyadenylated RNA from
CHX-treated H1
9 cells (Fig. 2C, lane 8). This result indicated that
this mRNA was initiated from an aberrant site not previously reported.
No primer-extended product corresponding to an RNA species with a 5'
end at nt 1631 was detected even in CHX-treated samples (data not
shown).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Determination of the structure of the H1 9 subgenomic
mRNA. 32P-end-labeled oligonucleotides representing various
regions of the HDV genome (A) were used to probe total RNA from
CHX-treated (as described in the legend to Fig. 1) and untreated H1 9
cells (B). (C) Oligonucleotide 63 was used for primer extension
analysis of poly(A)-selected RNA from CHX-treated and untreated H1 9
cells. Lanes 5 and 6, poly(A) and poly(A)+
RNA, respectively, from CHX-untreated H1 9 cells; lanes 7 and 8, poly(A) and poly(A)+ RNAs, respectively, from
CHX-treated H1 9 cells. A dideoxy sequence generated from plasmid
pKS/HDV1.9 by using oligonucleotide 63 served as a nucleotide sequence
marker (lanes 1 to 4).
|
|
These results indicated that the HDV subgenomic mRNA species detected
in various cDNA transfection systems have different origins of
transcription. Therefore, these transcripts may represent aberrant
transcription from cryptic promoters within the HDV cDNA. In all cases,
the reported 0.8-kb RNA species was not, or was only barely, detected.
Thus, the presence of HDV cDNA appears to interfere with the synthesis
of the authentic subgenomic mRNA species, probably because of the
presence of potent promoters in the HDV cDNA (19). This
phenomenon may have led to the previous interpretations that the
presence of HDAg inhibited the synthesis of the 0.8-kb RNA during HDV
RNA replication (9, 10).
Abundance of an HDV RNA-templated mRNA in a cDNA-free transfection
system.
The results presented above suggested that cDNA-initiated
transcription may interfere with the synthesis of the HDAg-encoding mRNA. To study the authentic mRNA synthesis of HDV RNA, we therefore adapted an RNA-only transfection system to detect the HDAg mRNA produced from the replicating HDV genome. Briefly, in vitro-transcribed genomic HDV RNA (1.9 kb, slightly longer than the monomer-size RNA) was
cotransfected with an in vitro-transcribed, capped, and polyadenylated
HDAg-encoding mRNA into Huh7 cells. This approach led to robust HDV RNA
replication in the transfected cells, as evidenced by the detection of
antigenomic-sense HDV monomer RNA (Fig.
3B, lane 5). A subgenomic RNA species was
also detected; however, it could not be distinguished from the mRNA
used for transfection (Fig. 3B, lane 5). To distinguish between the
mRNA produced from the genomic HDV template in the transfected cells and the exogenous mRNA used for transfection, we used for transfection a chimeric HDAg mRNA that contains sequences from both genotype I and
genotype II, whereas the genomic RNA (1.9 kb) used for transfection was
genotype I (Fig. 3A). This chimeric mRNA supported HDV RNA replication
(Fig. 3B, lane 6). Since the oligonucleotide probe used for Northern
blotting was specific for genotype I (nt 1565 to 1591), it detected the
genotype I mRNA (100% complementarity to nt 1565 to 1591) (lane 3) but
not the genotype I/II chimeric mRNA (55% complementarity to nt 1565 to
1591) (lane 4). Therefore, only the HDAg mRNA produced from the genomic
RNA (genotype I) as a result of HDV RNA replication, not the
transfected chimeric mRNA, would be detected (Fig. 3A; compare lanes 5 and 6). This probe also did not hybridize to the HDV RNA in H1
9
cells (lane 1), which express the Italian isolate of genotype I HDV
(20), since the Italian and American isolates of genotype I
HDV also diverge in the region probed (74% homology in nt 1565 to
1591). This finding further indicates the specificity of this
oligonucleotide probe. The result showed that a distinct 0.8-kb mRNA of
antigenomic sense, which represents the RNA derived from the HDV
monomer RNA, was synthesized at detectable levels (lane 6). The amount
of this RNA was far greater than that seen in any cDNA transfection
system reported so far. It is polyadenylated, whereas the genomic-size RNA does not contain poly(A) (Fig. 3C). Primer extension analysis of
the polyadenylated RNA mapped the 5' end to nucleotide 1631 (Fig. 3D,
lane 6), indicating that this RNA-templated HDAg mRNA was initiated
from the same site as the previously reported mRNA in a cDNA
transfection system (8). Significantly, no corresponding primer-extended product was detected in the poly(A)-deficient fraction
(Fig. 3D, lane 5), which represents all of the monomer-size RNA, even
though this fraction contained at least 10 times more HDV-specific
RNAs. Instead, a prominent band at nt 1646 was detected. This result
suggests that the HDV genomic RNA may be initiated from a different
site from the 0.8-kb mRNA species. As a control, this primer did not
generate any primer extension products on the in vitro-transcribed
chimeric mRNA used for transfection (Fig. 3D, lane 7).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
Detection of the 0.8-kb subgenomic mRNA in the cDNA-free
HDV RNA transfection system. (A) Schematic diagram of the mRNAs used
for transfection and the oligonucleotide probe used for detection. (B)
Total RNA harvested from Huh7 cells transfected with in
vitro-transcribed mRNA I alone (lane 3), chimeric mRNA I/II alone (lane
4), mRNA I plus in vitro-transcribed 1.9-kb genomic HDV RNA (lane 5),
or mRNA I/II plus 1.9-kb genomic HDV RNA (lane 6) was analyzed by
Northern blotting. 32P-end-labeled oligonucleotide 1565, which is specific for the American isolate of HDV genotype I
(22), was used as a probe. Total RNA extracted from H1 9
cells and from mock-transfected Huh7 cells (lane 2) served as controls.
(C) RNA isolated from Huh7 cells 4 days after transfection with 1.9-kb
HDV RNA plus mRNA I/II was separated into poly(A)+ and
poly(A) fractions and analyzed as for panel B. (D) Primer
extension analysis of the poly(A) RNA (lane 5),
poly(A)+ RNA (lane 6), and in vitro-transcribed mRNA I/II
(lane 7), using oligonucleotide 1565 as the probe. A dideoxy sequence
generated from plasmid pKS/HDV1.9 by using the same oligonucleotide
served as a nucleotide sequence marker (lanes 1 to 4).
|
|
The HDAg mRNA and HDV monomer are synthesized in parallel in the
presence of small HDAg.
The experiments described above
demonstrated the feasibility of this RNA-based transfection system for
the study of de novo RNA-templated synthesis of the full-length
antigenomic HDV RNA and HDAg mRNA. We next investigated the kinetics of
the synthesis of these two RNA species. Previous studies indicated that
HDAg could inhibit the production of the 0.8-kb HDAg-encoding mRNA in
an HDV cDNA-transfected system, probably as a result of the inhibition
of the polyadenylation signal in HDV cDNA or RNA (10). This
inhibition was seen with both the large and small HDAg (9). Based on these studies, Hsieh and Taylor proposed that the first round
of transcription on the HDV RNA template would produce the HDAg mRNA;
small HDAg translated from this mRNA would then suppress polyadenylation during subsequent rounds of RNA synthesis, allowing the
production of 1.7-kb antigenomic RNA (10). If this model is
correct, it is predicted that the 0.8-kb mRNA would be synthesized first, followed by synthesis of the 1.7-kb monomer RNA, and that the
0.8-kb mRNA would be synthesized only early in the viral replication cycle. To test this hypothesis, we analyzed HDV RNA and HDAg from days
1 through 5 in the RNA transfection system described above. The results
showed that the monomer RNA was detectable starting at day 2 and
increased in amount through day 4 (Fig.
4A). Particularly, there was a
significant increase between day 2 and day 3. Interestingly, the 0.8-kb
mRNA species started to be detectable at day 3, and there was a
particularly significant increase between days 3 and 4. There was a
slight decrease in both the monomer RNA and the 0.8-kb mRNA from days 4 to 5. Thus, the mRNA and monomer RNA increased in parallel. The
relative ratio between the monomer RNA and mRNA was determined by
phosphorimager analysis and was found to remain roughly the same
(approximately 3 in molar ratio except on day 2, when the amount of
HDAg mRNA was too small to be reliably determined) throughout the 5-day
period. The amount of HDAg in these cells was determined by
immunoblotting using a polyclonal antibody against HDAg. Figure 4B
shows that the small HDAg could be detected by day 3 and increased
through day 5. By day 4, the large HDAg became detectable as a result
of RNA editing, consistent with previous findings (18). It
is notable that despite the presence of a large amount of HDAg at days
3 to 4, the amount of 0.8-kb mRNA continued to increase, particularly
between days 3 and 4. This observation gave further support to the
conclusion that the 0.8-kb mRNA species detected represents newly
synthesized RNA but not merely stabilization of mRNA, since the
template for the mRNA encoding the large HDAg will not be generated
until an RNA editing event occurs late in infection (18).
The accumulation of large HDAg at days 4 and 5 may explain the slight
decrease in the amounts of both monomer RNA and the 0.8-kb mRNA at day
5, consistent with the previous finding that the large HDAg inhibits
HDV RNA synthesis (3). These data reveal several important
phenomena which contradict the current model for HDV mRNA synthesis
(10, 15, 16). First, the mRNA and antigenomic monomer RNA
are produced not sequentially but rather in parallel, suggesting that
there is not a switch from mRNA synthesis to monomer RNA synthesis.
Second, both species are still produced in the presence of HDAg,
suggesting that HDAg does not inhibit the production of its own mRNA.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Kinetics of the synthesis of antigenomic HDV RNA and
HDAg. Total RNA was isolated from Huh7 cells transfected with 1.9-kb
HDV genomic RNA plus mRNA I/II on days 1 through 5 posttransfection and
analyzed by Northern blotting using 32P-end-labeled
oligonucleotide 1565 as a probe (A). Arrows indicate the 1.7-kb
antigenomic HDV monomer and the 0.8-kb HDAg mRNA. (B) Protein isolated
from a similar experiment was analyzed by Western blotting with a
rabbit polyclonal antibody against HDAg. Arrows indicate the large
(27-kDa) and small (24-kDa) forms of HDAg.
|
|
 |
DISCUSSION |
We describe in this report a novel system for the unequivocal
detection of an HDAg-encoding mRNA transcribed from an HDV RNA. In this
cDNA-free RNA transfection system, abundant synthesis of a 0.8-kb,
polyadenylated, HDAg-encoding mRNA occurs during the HDV replication
cycle. Kinetic studies of the production of antigenomic-sense HDV RNA
in this system demonstrated that the amount of the RNA-templated
HDAg-encoding mRNA increases in parallel with the monomeric-length (1.7 kb) antigenomic HDV RNA from days 1 to 4 posttransfection, followed by
a slight decrease in both species from days 4 to 5 posttransfection.
The ratio of the 1.7- and 0.8-kb antigenomic HDV RNAs remains the same
throughout the replication cycle, despite increasing levels of HDAg.
The 5' end of the RNA-templated HDAg mRNA was mapped to nt 1631 by
primer extension analysis. We did not detect a similar primer-extended band in the poly(A)-deficient fraction of RNA from cells replicating HDV but instead detected another major band upstream of the initiation site for HDAg mRNA synthesis, at nt 1646.
The above findings lead to several conclusions regarding the mechanism
of HDV RNA replication and mRNA synthesis that contradict the current
model of HDV replication (Fig. 5A). The
current model (10, 15, 16) states that the 0.8-kb mRNA
represents the initial product of HDV RNA replication, which is
terminated by polyadenylation. Once HDAg is synthesized,
polyadenylation will be inhibited during subsequent rounds of RNA
synthesis, allowing elongation of the RNA transcript into multimeric
HDV RNA. Our studies here provide three critical pieces of evidence
contradicting this model. First, the HDV RNA polyadenylation signal
does not appear to be suppressed by HDAg in cell culture. This
conclusion is supported by our finding that HDAg mRNA synthesis
continues to increase despite increasing levels of HDAg. Second, the
HDAg mRNA may not be synthesized as the product of initiation of HDV RNA replication. This conclusion is supported by the finding that the
0.8-kb HDAg mRNA increases in parallel with the 1.7-kb antigenomic HDV
RNA; if the HDAg mRNA were the initial product of HDV RNA replication,
the mRNA would be predicted to appear only early in the HDV replication
cycle. Our findings are in direct contrast to this prediction. Third,
the mRNA and poly(A)
RNA (including HDV monomer RNA) may
have different initiation points. This conclusion is suggested by the
absence of a primer extension product at nt 1631 in poly(A)-deficient
RNA from cells containing replicating HDV RNA. Instead, a major primer
extension product at nt 1646 was detected in this fraction. This
nucleotide is located at the site complementary to nt 1631 in the
rod-like HDV RNA structure (14, 22, 31). Interestingly, this
complementary region encompassing both nt 1631 and nt 1646 in the HDV
cDNA has been shown to have a bidirectional promoter activity,
suggesting that nt 1646 may serve as a signal for initiation of RNA
synthesis (in the same orientation as the HDAg mRNA) (19).
Although we cannot rigorously rule out the possibility that the product
of initiation of RNA replication in the poly(A)
fraction
is quickly degraded, the fact remains that no evidence can be provided
to support a single initiation site for both the 0.8-kb HDAg mRNA and
the 1.7-kb antigenomic HDV RNA.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 5.
Proposed models of HDV RNA transcription and
replication. (A) The previously accepted model of HDV RNA transcription
and replication (10, 15, 16). The initial product of
replication from the genomic HDV RNA template is the 0.8-kb
HDAg-encoding mRNA (arrow 1). HDAg produced from this mRNA suppresses
the HDV polyadenylation signal, allowing synthesis of multimeric RNA
(arrow 2), which is processed into full-length antigenomic HDV RNA
(arrow 3). Subsequent rounds of replication bypass the polyadenylation
signal due to the presence of HDAg and directly synthesize full-length
antigenomic HDV RNA (arrow 4). (B) The proposed new model for HDV RNA
transcription and replication presented in this report. The syntheses
of 0.8-kb mRNA (a) and 1.7-kb monomer RNA (b) are independent and occur
in parallel.
|
|
The current model for HDV RNA replication and transcription was
developed from some critical assumptions regarding the mechanism of HDV
transcription and replication, only a few of which are supported by
experimental evidence. Essential to this model is the conclusion that
HDAg suppresses the HDV RNA polyadenylation signal, originally reached
by Hsieh and Taylor, who examined the effect of HDAg expression on an
HDV cDNA polyadenylation signal (10). While expression of
HDAg did appear to suppress the HDV cDNA polyadenylation signal, there
was not a corresponding increase in readthrough transcripts
(10). Therefore, HDAg may have functioned in these
experiments to suppress pol II transcription from the DNA promoter.
Indeed, preliminary evidence showed that HDAg has a capacity to inhibit
DNA-templated pol II transcription (17a). Subsequent
examination of the effects of HDAg on the HDV cDNA polyadenylation by
Hsieh et al. did reveal an increase in readthrough transcripts in the
presence of HDAg (9). However, reexamination of the data in
this experiment revealed that there was still abundant polyadenylated
transcript in the presence of HDAg. Thus, the observed effects of HDAg
in inhibiting polyadenylation may have been associated with
DNA-templated transcription. Furthermore, these studies (9, 10) showed that HDAg inhibited polyadenylation only when the HDV
cDNA included sequences covering almost the full 1.7-kb genome. This
result was interpreted to mean that a folded-back rod-like structure of
HDV RNA was required for HDAg suppression of polyadenylation (9,
10, 16); however, this cDNA structure may also produce endogenous
promoter activity in the HDV cDNA (19). Our studies presented here showed that when HDV RNA replication was initiated from
an RNA template, HDAg did not suppress the synthesis of the HDAg mRNA,
although we cannot entirely rule out the possibility that HDAg can
partially inhibit HDAg mRNA polyadenylation. Regardless, the parallel
increase in the 0.8-kb mRNA, the 1.7-kb antigenomic HDV RNA, and the
small form of HDAg between days 2 and 3 posttransfection argues that
HDV RNA replication is not dependent on the suppression of mRNA
transcription by HDAg. Therefore, HDV RNA replication and subgenomic
mRNA transcription may occur independently and in parallel throughout
the viral life cycle (Fig. 5B). This new view of HDV RNA transcription
and replication thus solves a puzzling question left unanswered by the
old model of HDV RNA transcription, namely, how can the mRNA for large
HDAg be synthesized late in infection if mRNA synthesis has already
been shut off by the small HDAg? However, a different question arises
as to how the polyadenylation signal is bypassed during RNA
replication. Determining the answer to this question will require
additional experimentation.
Another critical element of the current HDV replication model is the
hypothesis that the sites of initiation of both mRNA transcription and
genome replication are the same. This assumption has not been supported
by experimental evidence so far. Because transcription of a functional
mRNA for the expression of HDAg appears to be critical for replication
in natural HDV life cycle (13), any studies that attempt to
link the inhibition of mRNA initiation with inhibition of genome
replication may not be able to prove that these two processes represent
the same event. Recently, Wu et al. found that mutations at the top of
the genomic HDV RNA rod (in the region of the putative RNA promoter for
HDAg mRNA synthesis) which severely restricted HDV RNA replication
could be rescued by small HDAg provided in trans
(32). This finding suggests that sites critical for
initiation of mRNA transcription may not be critical for initiation of
replication. This is consistent with our data showing that the HDAg
mRNA and poly(A)
HDV RNA have different primer extension
products and thus may have different initiation points.
Finally, RNA pol II is hypothesized to be responsible for transcription
of both the HDAg mRNA and the 1.7-kb antigenomic HDV RNA. This
hypothesis is based on the finding that 1 µg of
-amanitin per ml
could inhibit HDV RNA-templated transcription in vitro H1
9 nuclear
extract; however, it is possible that this was a DNA-templated
transcription event, since the same authors were unable to inhibit HDV
transcription with
-amanitin from an exogenous HDV RNA template
added to HepG2 cells (21). Further, the relative sensitivities of synthesis of the various HDV RNA species (mRNA; 1.7-kb
genomic and antigenomic RNAs) to
-amanitin have not been assessed.
Thus, it is not clear whether mRNA transcription and genomic RNA
replication of HDV are carried out by the same polymerase and regulated
by the same mechanism. Our findings described here suggest the
tantalizing possibility that the 0.8-kb HDAg mRNA and the 1.7-kb
antigenomic RNA may be separately initiated but coordinately regulated.
This possibility will require further studies.
We thank C.-M. Lee (Chang-Gung Hospital, Kaoshiung, Taiwan) for
his generous gift of the HDV genotype II clones and K.-S. Jeng for the
tutoring and HDV plasmids on which this work depended.
L.E.M. is supported by a scholarship from the Life and Health Insurance
Medical Research Fund. M.M.C.L. is an Investigator of the HHMI.
| 1.
|
Casey, J. L.,
T. L. Brown,
E. J. Colan,
F. S. Wignall, and J. L. Gerin.
1993.
A genotype of hepatitis D virus that occurs in northern South America.
Proc. Natl. Acad. Sci. USA
90:9016-9020[Abstract/Free Full Text].
|
| 2.
|
Chang, F.-L.,
P.-J. Chen,
S.-J. Tu,
C.-J. Wang, and D.-S. Chen.
1991.
The large form of hepatitis antigen is crucial for assembly of hepatitis virus.
Proc. Natl. Acad. Sci. USA
88:8490-8494[Abstract/Free Full Text].
|
| 3.
|
Chao, M.,
S.-Y. Hsieh, and J. Taylor.
1990.
Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication.
J. Virol.
64:5066-5069[Abstract/Free Full Text].
|
| 4.
|
Chen, P.-J.,
G. Kalpana,
J. Goldberg,
W. Mason,
B. Werner,
J. L. Gerin, and J. Taylor.
1986.
Structure and replication of the genome of hepatitis delta virus.
Proc. Natl. Acad. Sci. USA
83:8774-8778[Abstract/Free Full Text].
|
| 5.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 6.
|
Geliebter, J.,
R. A. Zeff,
D. H. Schulze,
L. R. Pease,
E. H. Weiss,
A. L. Mellor,
R. A. Flavell, and S. G. Nathenson.
1986.
Interaction between Kb and Q4 gene sequences generates the Kbm6 mutation.
Mol. Cell. Biol.
6:645-652[Abstract/Free Full Text].
|
| 7.
|
Glenn, J. S.,
J. M. Taylor, and J. M. White.
1990.
In vitro-synthesized hepatitis delta virus RNA initiates genome replication in cultured cells.
J. Virol.
64:3104-3107[Abstract/Free Full Text].
|
| 8.
|
Hsieh, S.-Y.,
M. Chao,
L. Coates, and J. Taylor.
1990.
Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen.
J. Virol.
64:3192-3198[Abstract/Free Full Text].
|
| 9.
|
Hsieh, S.-Y.,
P.-Y. Yang,
J. T. Ou,
C. M. Chu, and Y. F. Liaw.
1994.
Polyadenylation of the mRNA of hepatitis delta virus is dependent on the structure of the nascent RNA and regulated by the small or large delta antigen.
Nucleic Acids Res.
22:391-396[Abstract/Free Full Text].
|
| 10.
|
Hsieh, S.-Y., and J. M. Taylor.
1991.
Regulation of polyadenylation of hepatitis delta virus antigenomic RNA.
J. Virol.
65:6438-6446[Abstract/Free Full Text].
|
| 11.
|
Hwang, S. B.,
K.-S. Jeng, and M. M. C. Lai.
1995.
Studies of functional roles of hepatitis delta antigen in delta virus RNA replication, p. 95-109.
In
G. Dinter-Gottlieb (ed.), The unique hepatitis delta virus. R. G. Landes Company, Austin, Tex.
|
| 12.
|
Jeng, K.-S.,
A. Daniel, and M. M. C. Lai.
1996.
A pseudoknot ribozyme structure is active in vivo and required for hepatitis delta virus RNA replication.
J. Virol.
70:2403-2410[Abstract].
|
| 13.
|
Kuo, M. Y.-P.,
M. Chao, and J. Taylor.
1989.
Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen.
J. Virol.
63:1945-1950[Abstract/Free Full Text].
|
| 14.
|
Kuo, M. Y.-P.,
J. Goldberg,
L. Coates,
W. Mason,
G. Gerin, and J. Taylor.
1988.
Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and application.
J. Virol.
62:1855-1861[Abstract/Free Full Text].
|
| 15.
|
Lai, M. M. C.
1995.
The molecular biology of hepatitis delta virus.
Annu. Rev. Biochem.
64:259-286[Medline].
|
| 16.
|
Lazinski, D. W., and J. M. Taylor.
1994.
Recent developments in hepatitis delta virus research.
Adv. Virus Res.
43:187-231[Medline].
|
| 17.
|
Lee, C.-M.,
C. S. Changchien,
J. C. Chung, and Y. F. Liaw.
1996.
Characterization of a new genotype II hepatitis delta virus from Taiwan.
J. Med. Virol.
49:145-154[Medline].
|
| 17a.
| Lo, K., and M. M. C. Lai. Unpublished
data.
|
| 18.
|
Luo, G.,
M. Chao,
S. Y. Hsieh,
C. Sureau,
K. Nishikura, and J. Taylor.
1990.
A specific base transition occurs on replicating hepatitis delta virus RNA.
J. Virol.
64:1021-1027[Abstract/Free Full Text].
|
| 19.
|
Macnaughton, T. B.,
M. R. Beard,
M. Chao,
E. J. Gowans, and M. M. C. Lai.
1993.
Endogenous promoters can direct the transcription of hepatitis delta virus RNA from a recircularized cDNA template.
Virology
196:629-636[Medline].
|
| 20.
|
Macnaughton, T. B.,
E. J. Gowans,
A. R. Jilbert, and C. J. Burrell.
1990.
Hepatitis delta virus RNA, protein synthesis and associated cytotoxicity in a stably transfected cell line.
Virology
177:692-698[Medline].
|
| 21.
|
Macnaughton, T. B.,
E. J. Gowans,
S. P. McNamara, and C. J. Burrell.
1991.
Hepatitis antigen is necessary for access of hepatitis virus RNA to the cell transcriptional machinery but is not part of the transcriptional complex.
Virology
184:387-390[Medline].
|
| 22.
|
Makino, S.,
M. F. Chang,
C. K. Shieh,
T. Kamahora,
D. M. Vannier,
S. Govindarajan, and M. M. C. Lai.
1987.
Molecular cloning and sequencing of a human hepatitis delta virus RNA.
Nature (London)
329:343-346[Medline].
|
| 23.
|
Nakabayashi, H.,
K. Taketa,
K. Miyano,
T. Yamane, and J. Sato.
1982.
Growth of human hepatoma cell lines with differentiated function in chemically defined medium.
Cancer Res.
42:3858-3863[Abstract/Free Full Text].
|
| 24.
|
Polo, J. M.,
K.-S. Jeng,
B. Lim,
S. Govindarajan,
F. Hofman,
F. Sangiorgi, and M. M. C. Lai.
1995.
Transgenic mice support replication of hepatitis delta virus RNA in multiple tissues, particularly in skeletal muscle.
J. Virol.
69:4880-4887[Abstract].
|
| 25.
|
Rizzetto, M.,
B. Hoyer,
M. G. Canese,
J. W.-K. Shih,
R. H. Purcell, and J. L. Gerin.
1980.
Delta agent: association of antigen with hepatitis B surface antigen and RNA in serum of -infected chimpanzees.
Proc. Natl. Acad. Sci. USA
77:6124-6128[Abstract/Free Full Text].
|
| 26.
|
Ross, J.
1995.
mRNA stability in mammalian cells.
Microbiol. Rev.
59:423-450[Abstract/Free Full Text].
|
| 27.
|
Ryu, W.-S.,
M. Bayer, and J. Taylor.
1992.
Assembly of hepatitis delta virus particles.
J. Virol.
66:2310-2315[Abstract/Free Full Text].
|
| 28.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
In
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
|
| 29.
|
Taylor, J.,
W. Mason,
J. Summers,
J. Golberg,
C. Aldrich,
L. Coates,
J. Gerin, and E. Gowans.
1987.
Replication of human hepatitis delta virus in primary cultures of woodchuck hepatocytes.
J. Virol.
61:2891-2895[Abstract/Free Full Text].
|
| 30.
|
Wang, E. H., and R. Tjian.
1994.
Promoter-selective transcriptional defect in cell cycle mutant ts13 rescued by hTAFII250.
Science
263:811-814[Abstract/Free Full Text].
|
| 31.
|
Wang, K. S.,
Q. L. Choo,
A. J. Weiner,
J. H. Ou,
R. C. Najarian,
R. M. Thayer,
G. T. Mullenbach,
K. J. Denniston,
J. L. Gerin, and M. Houghton.
1986.
Structure, sequence, and expression of the hepatitis delta viral genome.
Nature (London)
323:508-514[Medline].
|
| 32.
|
Wu, T.-T.,
H. J. Netter,
D. W. Lazinski, and J. M. Taylor.
1997.
Effects of nucleotide changes on the ability of hepatitis delta virus to transcribe, process, and accumulate unit-length, circular RNA.
J. Virol.
71:5408-5414[Abstract].
|